Armata Pharmaceuticals, Inc.(ARMP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ARMP Armata Pharmaceuticals, Inc.

Closed 12-18 16:00:00 EST

5.40

-0.26

-4.59%

盘后5.40

+0.000.00%

16:10 EST

High5.50	Low5.05	Vol47.09K
Open5.05	D1 Closing5.66	Amplitude7.95%
Mkt Cap196.60M	Tradable Cap58.72M	Total Shares36.41M
T/O247.33K	T/O Rate0.43%	Tradable Shares10.87M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ARMP","market":"US","secType":"STK","nameCN":"Armata Pharmaceuticals, Inc.","latestPrice":5.4,"timestamp":1766091600000,"preClose":5.66,"halted":0,"volume":47094,"hourTrading":{"tag":"盘后","latestPrice":5.4,"preClose":5.4,"latestTime":"16:10 EST","volume":3,"amount":16.2,"timestamp":1766092204393},"delay":0,"floatShares":10874618,"shares":36406905,"eps":-2.222998,"marketStatus":"Closed","change":-0.26,"latestTime":"12-18 16:00:00 EST","open":5.05,"high":5.5,"low":5.05,"amount":247330.6984,"amplitude":0.079505,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-2.222998,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1766134800000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"AMEX","adjPreClose":5.66,"preHourTrading":{"tag":"盘前","latestPrice":5.33,"preClose":5.66,"latestTime":"09:29 EST","volume":400,"amount":2081,"timestamp":1766068199999},"postHourTrading":{"tag":"盘后","latestPrice":5.4,"preClose":5.4,"latestTime":"16:10 EST","volume":3,"amount":16.2,"timestamp":1766092204393},"volumeRatio":1.839035,"impliedVol":1.3955,"impliedVolPercentile":0.228},"requestUrl":"/m/hq/s/ARMP/tweets","defaultTab":"tweets","newsList":[{"id":"2584346469","title":"Armata Pharmaceuticals Reports Positive Phase 2a Results for AP-SA02 in Staph Aureus Bacteremia","url":"https://stock-news.laohu8.com/highlight/detail?id=2584346469","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584346469?lang=en_us&edition=fundamental","pubTime":"2025-11-18 20:00","pubTimestamp":1763467259,"startTime":"0","endTime":"0","summary":"Armata Pharmaceuticals Inc., a clinical-stage biotechnology company specializing in bacteriophage therapeutics, announced that it will be featured in a key opinion leader webinar on November 25, 2025, focusing on Staphylococcus aureus  bacteremia and its investigational phage therapy, AP-SA02. The company previously presented positive results from its diSArm study at IDWeek 2025. The diSArm study was a Phase 1b/2a, multicenter, randomized, double-blind, placebo-controlled trial evaluating the safety, tolerability, and efficacy of intravenous AP-SA02 in combination with best available antibiotic therapy  versus BAT alone in adults with complicated S. aureus bacteremia. Results indicated that the combination of AP-SA02 and BAT achieved higher and earlier cure rates compared to BAT alone, with AP-SA02 showing a 100% response rate without relapse at key follow-up points, while the placebo group exhibited an approximate 25% relapse or lack of response. AP-SA02 was reported to be well-tolera","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL6CDWYR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INVA","BK4007","BK4139","ARMP"],"gpt_icon":0},{"id":"2583458800","title":"Armata Pharmaceuticals reports third quarter loss from operations of $7.8 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583458800","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583458800?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:15","pubTimestamp":1762982106,"startTime":"0","endTime":"0","summary":"Armata Pharmaceuticals Inc. reported a loss from operations of approximately $7.8 million for the third quarter ended September 30, 2025, compared to a loss of approximately $9.8 million for the same period in 2024. As of September 30, 2025, the company held around $14.8 million in unrestricted cash and cash equivalents, up from $9.3 million at the end of 2024. Approximately 36.3 million common shares were outstanding as of November 4, 2025. During the period, Armata highlighted positive results from the Phase 2a \"diSArm\" study of its lead therapeutic phage candidate, AP-SA02, for the treatment of complicated Staphylococcus aureus bacteremia, which were presented at IDWeek 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Armata Pha","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL6vqNml:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","ARMP","INVA"],"gpt_icon":0},{"id":"2583450588","title":"Armata Pharmaceuticals Secures $15 Million Loan from Innoviva Strategic Opportunities","url":"https://stock-news.laohu8.com/highlight/detail?id=2583450588","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583450588?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:09","pubTimestamp":1762981772,"startTime":"0","endTime":"0","summary":"Armata Pharmaceuticals Inc. has entered into a secured credit agreement with Innoviva Strategic Opportunities LLC, a wholly owned subsidiary of Innoviva, Inc. Under this agreement, Armata, whose largest shareholder is Innoviva, will receive a $15.0 million loan maturing on January 11, 2029. The proceeds from this financing are being used to advance the development of Armata's bacteriophage therapeutic candidate, AP-SA02.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Armata Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire  on November 12, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL6lpK1P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARMP","BK4007","BK4139","INVA"],"gpt_icon":0},{"id":"2583300066","title":"Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2583300066","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583300066?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:05","pubTimestamp":1762981502,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nTUA1KTCWC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ARMP"],"gpt_icon":0},{"id":"2582808258","title":"Armata Pharmaceuticals Commissions Manufacturing Facility in Los Angeles","url":"https://stock-news.laohu8.com/highlight/detail?id=2582808258","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582808258?lang=en_us&edition=fundamental","pubTime":"2025-11-10 23:32","pubTimestamp":1762788742,"startTime":"0","endTime":"0","summary":"Armata Pharmaceuticals  said Monday its Good Manufacturing Practice manufacturing facility in Los Angeles, California, has been commissioned.The company said it has notified the US Food and Drug Administration that production has started, and production runs have been completed with no issues.The plant allows Armata to make its multi-phage cocktails to support clinical trials, the company said.Price: 5.92, Change: +0.14, Percent Change: +2.42","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ARMP"],"gpt_icon":0},{"id":"2582808569","title":"Armata Pharmaceuticals trading resumes","url":"https://stock-news.laohu8.com/highlight/detail?id=2582808569","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582808569?lang=en_us&edition=fundamental","pubTime":"2025-11-10 23:15","pubTimestamp":1762787734,"startTime":"0","endTime":"0","summary":"10:10 EST Armata Pharmaceuticals (ARMP) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking finan...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/armata-pharmaceuticals-trading-resumes-thefly-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/armata-pharmaceuticals-trading-resumes-thefly-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ARMP"],"gpt_icon":0},{"id":"2582870297","title":"Amex Halt  Add Info Lst 5.810000","url":"https://stock-news.laohu8.com/highlight/detail?id=2582870297","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582870297?lang=en_us&edition=fundamental","pubTime":"2025-11-10 23:05","pubTimestamp":1762787159,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nAQN2L74UC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARMP","BK4139"],"gpt_icon":0},{"id":"2582739118","title":"BRIEF-Armata Pharmaceuticals Commissions cGMP Manufacturing Facility In Los Angeles","url":"https://stock-news.laohu8.com/highlight/detail?id=2582739118","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582739118?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:04","pubTimestamp":1762776246,"startTime":"0","endTime":"0","summary":"BRIEF-Armata Pharmaceuticals Commissions cGMP Manufacturing Facility In Los AngelesNov 10 (Reuters) - Armata Pharmaceuticals Inc ARMP.A:ARMATA PHARMACEUTICALS INC - COMMISSIONS CGMP MANUFACTURING FACI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nFWN3WM13E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARMP"],"gpt_icon":0},{"id":"2582736708","title":"Armata Pharmaceuticals Inc - FDA Notified of Production Commencement; No Issues Reported","url":"https://stock-news.laohu8.com/highlight/detail?id=2582736708","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582736708?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:02","pubTimestamp":1762776140,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nFWN3WM13E:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARMP","BK4139"],"gpt_icon":0},{"id":"2579323176","title":"Health Rounds: Viruses may hold key to tackling deadly bacterial infection","url":"https://stock-news.laohu8.com/highlight/detail?id=2579323176","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579323176?lang=en_us&edition=fundamental","pubTime":"2025-10-31 03:05","pubTimestamp":1761851116,"startTime":"0","endTime":"0","summary":"Health Rounds: Viruses may hold key to tackling deadly bacterial infectionHealth Rounds is published on Tuesdays and Thursdays. Think your friend or colleague should know about us?Forward this newsletter to them. They can also subscribe hereBy Nancy LapidOct 30  - Hello Health Rounds readers!","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nL1N3W919B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INVA","BK4007","ARMP"],"gpt_icon":0},{"id":"2577390360","title":"Amex Halt  Add Info Lst 7.930000","url":"https://stock-news.laohu8.com/highlight/detail?id=2577390360","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577390360?lang=en_us&edition=fundamental","pubTime":"2025-10-23 01:55","pubTimestamp":1761155709,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nAQN2L49OZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARMP","BK4139"],"gpt_icon":0},{"id":"2577212392","title":"Amex Halt  Add Info Lst 13.370000","url":"https://stock-news.laohu8.com/highlight/detail?id=2577212392","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577212392?lang=en_us&edition=fundamental","pubTime":"2025-10-23 01:11","pubTimestamp":1761153115,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nAQN2L49P2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ARMP"],"gpt_icon":0},{"id":"2577392543","title":"Amex Halt  Add Info Lst 13.750000","url":"https://stock-news.laohu8.com/highlight/detail?id=2577392543","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577392543?lang=en_us&edition=fundamental","pubTime":"2025-10-23 00:56","pubTimestamp":1761152172,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nAQN2L49P3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ARMP"],"gpt_icon":0},{"id":"2577239447","title":"Amex Halt  Add Info Lst 9.740000","url":"https://stock-news.laohu8.com/highlight/detail?id=2577239447","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577239447?lang=en_us&edition=fundamental","pubTime":"2025-10-23 00:35","pubTimestamp":1761150930,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nAQN2L49P5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARMP","BK4139"],"gpt_icon":0},{"id":"2577391277","title":"Amex Halt  Add Info Lst 7.320000","url":"https://stock-news.laohu8.com/highlight/detail?id=2577391277","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577391277?lang=en_us&edition=fundamental","pubTime":"2025-10-23 00:09","pubTimestamp":1761149356,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nAQN2L49P8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARMP","BK4139"],"gpt_icon":0},{"id":"2577391241","title":"Armata's Blood-Infection Drug Shows Positive Results in Mid-Stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2577391241","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577391241?lang=en_us&edition=fundamental","pubTime":"2025-10-23 00:06","pubTimestamp":1761149160,"startTime":"0","endTime":"0","summary":"Armata Pharmaceuticals said its experimental treatment for a serious bloodstream infection showed positive results in a recent mid-stage trial.The Los Angeles-based biotech company said Wednesday that its drug, AP-SA02, outperformed standard antibiotics in patients with complicated Staphylococcus aureus bacteremia, a severe and often life-threatening blood infection.In a Phase 2a study, patients receiving AP-SA02 alongside conventional antibiotics showed higher improvement rates than those given antibiotics alone. No patients in the AP-SA02 group experienced relapse or treatment failure during follow-up, compared with about 25% in the placebo group, the company said.Chief Executive Deborah Birx said Armata plans to advance AP-SA02 into a Phase 3 trial next year, pending Food and Drug Administration review.Shares jumped 95% to $6.78 before trading was paused for volatility.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SSI","BK4139","ARMP"],"gpt_icon":0},{"id":"2577391885","title":"Amex Halt  Add Info Lst 5.500000","url":"https://stock-news.laohu8.com/highlight/detail?id=2577391885","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577391885?lang=en_us&edition=fundamental","pubTime":"2025-10-22 23:48","pubTimestamp":1761148125,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nAQN2L49PA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARMP","BK4139"],"gpt_icon":0},{"id":"2577839929","title":"Armata data support advancing AP-SA02 to Phase 3, says H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2577839929","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577839929?lang=en_us&edition=fundamental","pubTime":"2025-10-22 23:40","pubTimestamp":1761147610,"startTime":"0","endTime":"0","summary":"H.C. Wainwright reiterates a Buy rating and $9 price target on Armata Pharmaceuticals (ARMP) after the company shared new data from the recently co...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/armata-data-support-advancing-ap-sa02-to-phase-3-says-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/armata-data-support-advancing-ap-sa02-to-phase-3-says-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ARMP"],"gpt_icon":0},{"id":"2577399244","title":"Armata Pharmaceuticals up 19% after reporting results of diSArm study","url":"https://stock-news.laohu8.com/highlight/detail?id=2577399244","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577399244?lang=en_us&edition=fundamental","pubTime":"2025-10-22 23:35","pubTimestamp":1761147316,"startTime":"0","endTime":"0","summary":"Armata Pharmaceuticals (ARMP) shares jumped 67c, or 19%, to $4.17 after resuming trading. Published first on TheFly – the ultimate source for real-...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/armata-pharmaceuticals-up-19-after-reporting-results-of-disarm-study-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/armata-pharmaceuticals-up-19-after-reporting-results-of-disarm-study-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ARMP"],"gpt_icon":0},{"id":"2577399612","title":"Amex Halt  Add Info Lst 4.150100","url":"https://stock-news.laohu8.com/highlight/detail?id=2577399612","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577399612?lang=en_us&edition=fundamental","pubTime":"2025-10-22 23:31","pubTimestamp":1761147098,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nAQN2L49PB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ARMP"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.armatapharma.com","stockEarnings":[{"period":"1week","weight":-0.0018},{"period":"1month","weight":-0.1565},{"period":"3month","weight":0.8993},{"period":"6month","weight":1.9326},{"period":"1year","weight":1.83},{"period":"ytd","weight":2.0595}],"compareEarnings":[{"period":"1week","weight":-0.0235},{"period":"1month","weight":0.0086},{"period":"3month","weight":0.0138},{"period":"6month","weight":0.1298},{"period":"1year","weight":0.1111},{"period":"ytd","weight":0.1456}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.8,"avgChangeRate":0.25596},{"month":2,"riseRate":0.6,"avgChangeRate":0.039234},{"month":3,"riseRate":0.3,"avgChangeRate":-0.081811},{"month":4,"riseRate":0.3,"avgChangeRate":-0.09292},{"month":5,"riseRate":0.5,"avgChangeRate":-0.085814},{"month":6,"riseRate":0.4,"avgChangeRate":-0.037845},{"month":7,"riseRate":0.5,"avgChangeRate":0.13266},{"month":8,"riseRate":0.4,"avgChangeRate":0.045256},{"month":9,"riseRate":0.454545,"avgChangeRate":-0.050116},{"month":10,"riseRate":0.363636,"avgChangeRate":-0.021708},{"month":11,"riseRate":0.454545,"avgChangeRate":0.010332},{"month":12,"riseRate":0.181818,"avgChangeRate":-0.115846}],"exchange":"AMEX","name":"Armata Pharmaceuticals, Inc.","nameEN":"Armata Pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Armata Pharmaceuticals, Inc.(ARMP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Armata Pharmaceuticals, Inc.(ARMP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Armata Pharmaceuticals, Inc.,ARMP,Armata Pharmaceuticals, Inc.股票,Armata Pharmaceuticals, Inc.股票老虎,Armata Pharmaceuticals, Inc.股票老虎国际,Armata Pharmaceuticals, Inc.行情,Armata Pharmaceuticals, Inc.股票行情,Armata Pharmaceuticals, Inc.股价,Armata Pharmaceuticals, Inc.股市,Armata Pharmaceuticals, Inc.股票价格,Armata Pharmaceuticals, Inc.股票交易,Armata Pharmaceuticals, Inc.股票购买,Armata Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Armata Pharmaceuticals, Inc.(ARMP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Armata Pharmaceuticals, Inc.(ARMP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction